Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) total scores during treatment with omalizumab (ITT population).

<p>Change from baseline in Asthma Quality of Life Questionnaire (AQLQ) total scores during treatment with omalizumab (ITT population).</p

Mean change in total annual oral corticosteroid (OCS) dose [¹] (ITT population).

<p>Mean change in total annual oral corticosteroid (OCS) dose [^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0183869#t002fn001" target="_blank">1</a>}] (ITT population).</p

Change from baseline in Asthma Control Questionnaire (ACQ) total score [¹] during the prospective period (ITT population).

<p>Change from baseline in Asthma Control Questionnaire (ACQ) total score [^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0183869#t004fn001" target="_blank">1</a>}] during the prospective period (ITT population).</p

Change from baseline in Forced Exhaled Nitric Oxide (FeNO) mean values [¹] during the prospective period (ITT / FeNO population).

<p>Change from baseline in Forced Exhaled Nitric Oxide (FeNO) mean values [^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0183869#t006fn001" target="_blank">1</a>}] during the prospective period (ITT / FeNO population).</p

Percent change in total annual OCS dose and number of severe asthma exacerbations in Low/High FeNO baseline subgroups from baseline to end of prospective period (ITT population).

<p>Percent change in total annual OCS dose and number of severe asthma exacerbations in Low/High FeNO baseline subgroups from baseline to end of prospective period (ITT population).</p

Number (%) of subjects experiencing severe asthma exacerbations [¹] and change from baseline health resource utilization (ITT population).

<p>Number (%) of subjects experiencing severe asthma exacerbations [^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0183869#t003fn001" target="_blank">1</a>}] and change from baseline health resource utilization (ITT population).</p

Demographics and baseline characteristics.

<p>Demographics and baseline characteristics.</p

All Serious adverse events.

<p>All Serious adverse events.</p